Idaho’s 2024 PBM reform (HB 596, effective January 1, 2025) requires pass-through pricing and bans spread pricing, sets network-adequacy and anti-steering rules, bars retroactive clawbacks, and provides a MAC appeal — but it does not create a commercial NADAC reimbursement floor.
The only acquisition-cost language is a remedy: if a generic-drug MAC appeal is upheld, the PBM must reset the MAC to at least the appealing pharmacy’s acquisition cost. That is an appeal outcome, not a floor on every claim. (Idaho’s Medicaid program separately reimburses on actual acquisition cost plus a dispensing fee, which is a Medicaid rule rather than the commercial PBM law.)